Phase 3 Trial Results of Stelara for Crohn’s Disease Indicate Promising Results

Phase 3 Trial Results of Stelara for Crohn’s Disease Indicate Promising Results
Janssen Pharmaceuticals’ drug candidate Stelara (ustekinumab) demonstrated positive therapeutic effects in a recent Phase 3 clinical trial, inducing clinical response and remission in adult patients with moderate to severe Crohn’s disease who had been treated with anti-tumor necrosis factor (TNF)-alpha therapy and were either unresponsive or intolerant to it. The efficacy and safety results from the Second Stelara Phase 3 Induction Study (UNITI-1) were presented at the 11th Congress of the European Crohn's and Colitis Organization. Janssen has
Subscribe or to access all post and page content.